L6H21 | LPS-TLR4/MD-2 Inhibitor

L6H21
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565158

CAS#: 24533-47-9

Description: L6H21 is an inhibitor of the interaction and signaling transduction of LPS-TLR4/MD-2 (myeloid differentiation 2).

Chemical Structure

L6H21

CAS# 24533-47-9

Instruction

Theoretical Analysis

MedKoo Cat#: 565158
Name: L6H21
CAS#: 24533-47-9
Chemical Formula: C18H18O4
Exact Mass: 298.12
Molecular Weight: 298.340
Elemental Analysis: C, 72.47; H, 6.08; O, 21.45

Price and Availability

Size	Price	Availability
5mg	USD 285	2 Weeks
25mg	USD 850	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: L6H21; L6H 21; L6H-21;

IUPAC/Chemical Name: (E)-2,3-dimethoxy-4'-methoxychalcone

InChi Key: IECVLMVZGCYCSZ-FMIVXFBMSA-N

InChi Code: InChI=1S/C18H18O4/c1-20-15-10-7-13(8-11-15)16(19)12-9-14-5-4-6-17(21-2)18(14)22-3/h4-12H,1-3H3/b12-9+

SMILES Code: O=C(C1=CC=C(OC)C=C1)/C=C/C2=CC=CC(OC)=C2OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 298.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Yu FZ, Wen X, Ding WL, Zhu JY, Du SH, Shen QF, Ni X, Wang J. L6H21 prolonged rats survival after limb allotransplantation by inhibiting acute rejection. Eur Rev Med Pharmacol Sci. 2017 Apr;21(8):1891-1903. PubMed PMID: 28485788.

2: Wang Y, Shan X, Chen G, Jiang L, Wang Z, Fang Q, Liu X, Wang J, Zhang Y, Wu W, Liang G. MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br J Pharmacol. 2015 Sep;172(17):4391-405. doi: 10.1111/bph.13221. Epub 2015 Jul 21. PubMed PMID: 26076332; PubMed Central PMCID: PMC4556476.

3: Hong GL, Yang ZN, He YY, Tan JP, Liangm A, Zhao GJ, Lu ZQ. [Mono-carbonyl analogues of curcumin prevents paraquat-induced apoptosis in HK-2 cell line by inhibiting oxidative damage and inflammation]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2017 Sep 20;35(9):641-647. doi: 10.3760/cma.j.issn.1001-9391.2017.09.001. Chinese. PubMed PMID: 29294513.

4: Chen X, Yu W, Li W, Zhang H, Huang W, Wang J, Zhu W, Fang Q, Chen C, Li X, Liang G. An anti-inflammatory chalcone derivative prevents heart and kidney from hyperlipidemia-induced injuries by attenuating inflammation. Toxicol Appl Pharmacol. 2018 Jan 1;338:43-53. doi: 10.1016/j.taap.2017.11.003. Epub 2017 Nov 8. PubMed PMID: 29128402.

5: Zhang Y, Wu B, Zhang H, Ge X, Ying S, Hu M, Li W, Huang Y, Wang L, Chen C, Shan X, Liang G. Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease. J Cell Mol Med. 2018 Feb;22(2):936-947. doi: 10.1111/jcmm.13395. Epub 2017 Oct 27. PubMed PMID: 29077272; PubMed Central PMCID: PMC5783870.

6: Fang Q, Wang J, Zhang Y, Wang L, Li W, Han J, Huang W, Liang G, Wang Y. Inhibition of myeloid differentiation factor-2 attenuates obesity-induced cardiomyopathy and fibrosis. Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):252-262. doi: 10.1016/j.bbadis.2017.09.026. Epub 2017 Sep 29. PubMed PMID: 28965884.

7: Fang Q, Wang L, Yang D, Chen X, Shan X, Zhang Y, Lum H, Wang J, Zhong P, Liang G, Wang Y. Blockade of myeloid differentiation protein 2 prevents obesity-induced inflammation and nephropathy. J Cell Mol Med. 2017 Dec;21(12):3776-3786. doi: 10.1111/jcmm.13287. Epub 2017 Aug 2. PubMed PMID: 28767204; PubMed Central PMCID: PMC5706499.

8: Xu Z, Li W, Han J, Zou C, Huang W, Yu W, Shan X, Lum H, Li X, Liang G. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Sci Rep. 2017 Mar 21;7:44911. doi: 10.1038/srep44911. PubMed PMID: 28322341; PubMed Central PMCID: PMC5359637.

9: Han J, Zou C, Mei L, Zhang Y, Qian Y, You S, Pan Y, Xu Z, Bai B, Huang W, Liang G. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway. Basic Res Cardiol. 2017 Jan;112(1):9. doi: 10.1007/s00395-016-0599-5. Epub 2016 Dec 24. PubMed PMID: 28013347.

10: Fang Q, Zhao L, Wang Y, Zhang Y, Li Z, Pan Y, Kanchana K, Wang J, Tong C, Li D, Liang G. A novel chalcone derivative attenuates the diabetes-induced renal injury via inhibition of high glucose-mediated inflammatory response and macrophage infiltration. Toxicol Appl Pharmacol. 2015 Jan 15;282(2):129-38. doi: 10.1016/j.taap.2014.10.021. Epub 2014 Nov 8. PubMed PMID: 25447405.

Your view history

L6H21 featured